Parkinson's Disease
Conditions
Keywords
Parkinson's disease, Deep brain stimulation, Gait, Freezing, Electrode placements
Brief summary
Deep brain stimulation of STN (subthalamic nucleus) at high frequencies generally improved gait in parkinsonian patients. However, sometimes the investigators observed a gait aggravation either with using high voltage and high frequencies, either because of suboptimal placement of electrode inside Forel H2 field. The most frequent hypothesise to explain this gait aggravation is a modulation of the activity of pedunculopontine nucleus due to a diffusion of the electric stimulation current to the fibbers going near STN area. The primary purpose of this study is to compare the effect of deep brain stimulation with high frequency versus low frequency on gait of patients whatever the electrodes placement (STN ou Forel fields) and whatever the medication condition (with or without treatment).
Detailed description
A randomized, double-blind, parallel-group study 2 groups of patients: 10 patients with electrodes placed in STN and 10 patients with electrodes placed in Forel fields. 1 group of healthy paired-control (n=20). Patients will be evaluated without and with treatment on two mornings (J0 and J0+1day). In each condition of treatment, 3 conditions of stimulation were tested: without stimulation; frequency 25Hz, frequency 130 Hz. Evaluations consist on : * motor evaluation (UPDRS) * gait evaluation (to walk on a gait mat) * Stand-Walk-Sit Test
Interventions
BEHAVIORALdeep brain stimulation
Sponsors
University Hospital, Clermont-Ferrand
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients : * Men or women aged between 45 -85 years * Patients with an idiopathic Parkinson's disease according to UKPDSBB criteria * Normal neurologic evaluation (except Parkinson's disease) * Patient treated with a deep brain stimulation according to the French consensus conference of treatment of Parkinson's disease (Consensus Conference Proceeding, 2000) * Affiliated to National Health system * Having given their informed consent Healthy subject * Men or women aged between 45 -85 years * Normal neurologic evaluation * Affiliated to National Health system * Having given their informed consent
Exclusion criteria
* Patients : * Patients suffering of an atypical Parkinson syndrome * Patients with locomotive disorders which can interfere in gait evaluation * Patients with dementia (MMS \<24) * Under guardianship * In excluding period for another study * Person who participate to an other study Healthy subject * Subject with locomotive disorders which can interfere in gait evaluation * Subject with dementia (MMS \<24) * Under guardianship * In excluding period for another study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The step length (expressed in meter) | from day 1 (without L Dopa) to day 2 (with L Dopa) |
Secondary
| Measure | Time frame |
|---|---|
| The gait speed | from day 1 (without L Dopa) to day 2 (with L Dopa) |
| The step cadence | From day 1 (without L Dopa) to day 2 (with L Dopa) |
| The number of freezing | from day 1 (without L Dopa) to day 2 (with L Dopa) |
| The UPDRS score | from day 1 (without L Dopa) to day 2 (with L Dopa) |
Countries
France
Outcome results
None listed